General Child Neurology
Acute cerebellar ataxia in children
Oct. 29, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Hemispheric low-grade gliomas and neuronal and glioneuronal tumors of childhood …
- Updated 12.29.2023
- Released 10.14.1996
- Expires For CME 12.29.2026
Hemispheric low-grade gliomas and neuronal and glioneuronal tumors of childhood
Introduction
Overview
Supratentorial low-grade gliomas and neuronal mixed neuronal-glial tumors are comprised of a variety of different histological subtypes. In the revised “2021 WHO Classification of CNS Tumors,” the glial tumors will be either pediatric-type diffuse low-grade gliomas or circumscribed astrocytic tumors, predominantly pilocytic astrocytomas. Fourteen distinct subvarieties of glioneural and neuronal tumors are recognized (85). Outcome is excellent after gross total resection, but some tumors may arise from infiltration of critical areas of brain structure where aggressive surgery is relatively contraindicated. For these lesions, radiation therapy and, in some cases, chemotherapy may be indicated. In addition, biologically based therapy utilizing molecular-targeted agents is becoming an increasing reality. The author summarizes these new approaches and the clinical implications of new biological insights. New molecular information has been added and its clinical implications discussed.
Key points
|
• The most common presentation of supratentorial low-grade gliomas and neuronal mixed neuronal-glial tumors of childhood is a seizure. | |
|
• Supratentorial, pilocytic astrocytomas of childhood and some and neuronal and mixed neuronal-glial tumors can be cured after total resection without any additional chemotherapy. | |
|
• Differential diagnosis may be difficult in infancy, as congenital astrocytomas may be difficult to classify. |
Historical note and terminology
Supratentorial low-grade gliomas of childhood are a subset of primary central nervous system tumors, comprising a variety of different histological types. These low-grade tumors have an extremely variable growth rate, which, although somewhat related to the histological subtype of the tumor, may be relatively unpredictable even within a single glial subtype. These tumors have been subdivided primarily on the basis of their cytologic architecture. In the 1920s, Bailey and Cushing separated childhood low-grade supratentorial low-grade glial tumors into predominantly protoplasmic or fibrillary types (04). As time has gone on, many other classification schemas have been used. The terms "diffuse," "protoplasmic," and "gemistocytic" have been used by some authors. Russell and Rubinstein used the descriptive terms "fibrillary," "protoplasmic," "pilocytic," and "gemistocytic" to classify the majority of low-grade cerebral gliomas (114). The Kernohan grading system separated low-grade gliomas into either grade 1 or grade 2 astrocytomas, using grades 3 and 4 to designate malignant tumors (64). In the World Health Organization histological typing of central nervous system tumors, low-grade gliomas were classified primarily under the nomenclature of “astrocytoma” and then subdivided into fibrillary, protoplasmic, or gemistocytic astrocytomas (68; 83). The pilocytic astrocytoma has been given its own separate subgroup. Other tumor types believed to be of glial lineage, such as the pleomorphic xanthoastrocytoma and subependymal giant astrocytoma, have also been placed within the astrocytoma grouping.
By convention, other tumor types are often included in the general category of low-grade glial tumors. Oligodendroglial tumors and mixed gliomas do not have frank areas of histological anaplasia, and are often included in series reviewing childhood low-grade cortical tumors. Astroblastoma is a distinctive tumor that some authors have considered to have a poor prognosis but other authors have considered to be a relatively benign form of childhood glioma. In the 2016 World Health Organization classification of central nervous system tumors, pilocytic astrocytoma, subependymal giant cell astrocytoma, and angiocentric glioma are considered grade 1 tumors. Diffuse astrocytoma is considered a grade 2 lesion, with the IDH mutant being a distinct entity, which infrequently arises in pediatric-aged patients until adolescents or the teenage years. Pleomorphic xanthoastrocytoma is also a grade 2 lesion (84).
Low-grade astrocytomas may also be intermixed with cells that are apparently neuronally derived. These neuronal and mixed neuronal-glial tumors are also often included in series reviewing childhood low-grade glial tumors. In the World Health Organization categorization, tumors composed predominantly of mature ganglion cells with a minor component of supportive non-neoplastic glial cells have been termed "gangliocytomas." The term "ganglioglioma" has been used predominantly to designate a tumor where there seems to be neoplastic neuronal cells intermixed with predominantly glial neoplastic cells. Two more tumor types, the desmoplastic infantile ganglioglioma and the dysembryoplastic neuroepithelial tumor, have also been included in reviews of low-grade cortical tumors (125; 127; 27). Other rare forms of mixed neuronal tumors are also included in the 2017 WHO classification schema (84). In very low-grade diffuse tumors, separation of the leading edge of the low-grade tumor from normal surrounding brain is often microscopically impossible. Arbitrary decisions are often made concerning whether a lesion is a true low-grade glioma or an area of reactive gliosis. Molecular understandings have dramatically affected classification and insights into tumor pathogenesis.
The 2021 revised WHO classification of central nervous system tumors increasingly includes molecular subclassification (85). This is discussed in detail in the biological basis section (102; 25; 24; 116; 82; 59; 98; 115; 30). Combined molecular and epigenetic (including methylation data) are changing how these tumors are classified, but more conventional histologic features need to be incorporated cannot be for the most impactful understanding of an individual tumor (36). Some diffuse low-grade gliomas and glioneuronal tumors are diagnosed on the basis of molecular finding, including methylation clustering (36).
Table 1. WHO Classification of Low-Grade Glial and Glioneuronal Tumor
|
Pediatric-type diffuse low-grade gliomas |
|
• Diffuse astrocytoma, MYB- or MYBL1-altered |
|
Circumscribed astrocytic gliomas |
|
• Pilocytic astrocytoma |
|
• High-grade astrocytoma with piloid features |
|
Glioneuronal and neuronal tumors |
|
• Ganglioglioma |
|
• Diffuse glioneuronal tumor with oligodendroglioma like features and nuclear clusters |
Clinical manifestations
Presentation and course
The clinical presentations of hemispheric supratentorial low-grade gliomas and neuronal and mixed neuronal-glial tumors are related predominantly to the area of brain from which the astrocytomas arise (86; 39). The most common presentations are nonspecific and nonlocalizing headaches. Seizures are another frequent presenting symptom and are more common in lower-grade lesions than in high-grade gliomas. Any type of seizure may occur, including focal seizures with secondary generalization, complex partial seizures, and generalized seizures. Seizures may precede diagnosis by months to years. With the wider use of epilepsy surgery for patients with intractable epilepsy, an increasing number of children with longstanding seizures and apparently static or slowly progressing cortical (especially temporal and, to a lesser degree, frontal) lesions are found to harbor low-grade glial tumors or mixed neuronal and glial low-grade tumors (gangliogliomas).
Focal neurologic deficits, especially focal motor deficits, are common presenting symptoms in pediatric patients, occurring in up to 40% of children with low-grade tumors. Sensory deficits are less common in pediatrics. Rarely, a frontal lobe lesion may present with apparent ataxia, believed to be due to involvement of fronto-pontine pathways.
Children with tuberous sclerosis are at risk of developing subependymal giant cell astrocytomas. Such lesions are often intraventricular and can cause obstructive hydrocephalus (72). Children with NF1 may present as patients without NF1, but also may have lesions found on “screening” studies when they are apparently asymptomatic.
The differential diagnosis in a child with a supratentorial mass lesion is varied. Abscesses, chronic granulomatous lesions, and cerebrovascular accidents may mimic low-grade neoplasms. Other primary central nervous system tumors that relatively frequently arise in the supratentorial region in childhood include high-grade gliomas, primitive neuroectodermal tumors, ependymomas, choroid plexus carcinomas, and choroid plexus papillomas. As stated previously, low-grade astrocytomas outnumber high-grade neoplasms in childhood by a ratio of at least 2:1, and in some series by a ratio of closer to 4:1. The only way to clearly separate tumor types is by biopsy. However, for specific diagnosis, a relatively large sample of the tumor must be histologically studied. Biopsies or small resections may give misleading information due to sampling error. A variety of immunohistochemical diagnostic techniques, especially proliferation markers, are being evaluated for their specificity and sensitivity in distinguishing between higher-grade tumors and those that will act more benignly. These techniques include staining for the Ki-67 antigen, and an antibody to MIB-1, which is also thought to identify the Ki-67 antigen (22; 87). These proliferation markers have been used to predict outcome for adults and children with low-grade neoplasms. However, they have not been widely incorporated, as of yet, into classification schemas for childhood central nervous system tumors. Other tests, such as PET and SPECT, may suggest the presence of a low-grade neoplasm rather than a high-grade tumor, as low-grade tumors have a metabolism similar to that of surrounding brain.
Prognosis and complications
The overall prognosis for children with low-grade cortical gliomas and neuronal and mixed neuronal-glial tumors is relatively good compared to other forms of childhood central nervous system malignancy. The average 10-year rate of survival for those patients diagnosed before the age of 20 years is over 90% (17; 40). Some histological patterns have been associated with better outcome. Pilocytic astrocytomas, gangliogliomas, and some rarer infantile tumors (desmoplastic infantile gangliogliomas, dysembryonic neuroepithelial tumors, and possibly xanthoastrocytoma) have been associated with better outcome (114; 38; 128). Within the pediatric-type diffuse gliomas, tumors with BRAF fusions seem to have the best prognosis and lowest chance of malignant transformation (29). Postoperative regression has been noted in desmoplastic infantile gangliogliomas (124). As stated previously, children with low-grade gliomas have better prognoses than do adults for long-term survival; however, it is unclear at what age a patient can be considered to have an adult prognosis. This is likely a factor of biology, not age (122). Childhood low-grade supratentorial gliomas rarely mutate into higher-grade lesions, whereas the majority of adult tumors mutate over three to five years after diagnosis (47). However, this might not be true for those tumors with a BRAF v600E mutation (76). Also, co-deletion of CDKN2A suggested poorer prognosis and a tendency to mutate to a higher-grade glioma (19; 76). In a retrospective review of 461 patients with cortical low-grade tumors, the 15-year survival rate was over 80% for patients under 19 years of age, as compared to less than 40% for older patients (77). Other variables associated with increased survival included lack of major preoperative neurologic deficits, longer duration of symptoms prior to surgery, seizures at the presentation of illness, and lack of major postoperative neurologic deficits.
Although some histological types of low-grade gliomas may be related to different rates of survival, the separation of tumors by grading has been variably related to survival. In general, when pilocytic tumors are considered to be grade 1 lesions, survival is better for grade 1 lesions than for grade 2 lesions. On the other hand, when grade 1 and grade 2 lesions have been separated by alternative classification systems using other histological criteria, the relationship between grading and outcome is less clear (33). Hoshino has found an association between proliferative indices, such as bromodeoxyuridine labeling, and outcome; both children and adults who have lower labeling indices have a better prognosis (56; 22). MIB-1 proliferative index has been shown to predict survival in grade 2 astrocytomas (91). Pilomyxoid chiasmatic tumors have been associated with poorer prognosis (70). It is likely the most important factor in prognosis is the molecular alteration of the tumor (29; 85).
Clinical vignette
A seven-year-old boy was referred for evaluation of seizures that had developed over the past year. The seizures initially began as focal seizures involving the left arm, but, before the evaluation, generalized seizures had been noted. There were also episodes of staring.
On clinical examination, the child was alert and oriented. His pupils were equal and reactive, and his discs were flat. Extraocular movements were full, and the remainder of his cranial nerves was normal. Motor and coordination testing was completely within normal limits. Reflexes were two out of four and symmetric, and toes were down-going.
On CT, no specific abnormalities were noted. On MRI, an ill-defined hypodensity on T1-weighted images and an increased intensity on T2-weighted images were seen in the right temporal lobe. There was mild heterogeneous contrast enhancement.
Biological basis
Etiology and pathogenesis
The etiology of supratentorial low-grade gliomas neuronal and mixed neuronal-glial tumors is essentially unknown for the majority. There is a higher incidence of supratentorial low-grade tumors in children with neurofibromatosis type 1; however, this relationship is not as strong as the relationship between hypothalamic low-grade gliomas and neurofibromatosis type 1 (18).
Children with tuberous sclerosis are at risk for development of subependymal giant cell astrocytomas (72; 35). Those children with p53 germ-line mutations (Li-Fraumeni syndrome) and mismatch repair mutations have a greater likelihood of developing low-grade gliomas that transform into higher-grade tumors.
The molecular pathogenesis of pediatric low-grade gliomas and neuronal and mixed neuronal glial tumors is increasingly understood. For many years the relationship between NF1 and the development of low-grade gliomas was recognized, and more recently gangliogliomas have also been associated with NF1 (95). The majority of patients with NF1 and presumed low-grade gliomas do not undergo surgery because many lesions are indolent, being found on screening aminations and are considered “incidental” findings; they are presumed to be pilocytic astrocytomas (95). Those lesions that cause neurologic compromise are more likely to be biopsied. In older children and especially young adults, some NF1-associated low-grade gliomas have been found to harbor additional mutational changes such as CDKN2A/B, or ATRX, or both mutations and tend to act more aggressively (109). Such “anaplastic” piloid astrocytomas are difficult to manage.
Pilocytic astrocytomas are composed of elongated cells with tapering processes. They may be microcystic or have a large single cyst associated with a tumor nodule. Tumor cells in pilocytic astrocytomas tend to form compact parallel bundles, there is often a biphasic pattern where the pilocytic areas are intermixed with more loosely structured microcystic regions (114). A variant of the pilocytic astrocytomas, the pilomyxoid astrocytoma, was described in 1999 as a pediatric tumor with monomorphous piloid features. It was believed to a have poorer prognosis than the classical pilocytic astrocytoma and possibly a greater tendency to disseminate to the nervous system (69). In the 2016 WHO classification pilomyxoid astrocytomas are not considered a separate entity although molecular studies have shown that some have a different gene expression profile; there is a tendency in some cases to mature to more of a classic pilocytic astrocytoma subtype (69).
BRAF genetic alterations associated with increased signaling through the RAS/MAPK pathway occur in the majority of children with non-NF1 associated pilocytic astrocytomas (60). The most common mutation seen is the KIAA1549:BRAF gene fusion. The resultant fusion protein lacks the BRAF regulatory domain, which causes increased signaling through the MAPK pathway. The fusion underlies the majority of cerebellar, and to a lesser extent, diencephalic low-grade gliomas. It is present at a lower frequency in supratentorial low-grade gliomas. BRAFV600E mutations are seen in pilocytic astrocytomas but can also be seen in other forms of low-grade gliomas, especially diffuse astrocytic tumors (102; 60; 07; 113; 61; 30). FGRR1 mutations are the third most common molecular genetic abnormalities seen. FGFR2 mutations are seen less commonly. Multiomic neuropathology increases accuracy in diagnosis (121).
The fibrillary variant of pediatric low-grade astrocytomas is comprised of cells with predominantly hyperchromatic, oval to regular nuclei (114). This tumor type would now be considered under the grouping of pediatric-type diffuse low-grade gliomas. The cytoplasm of these cells can be fairly scant. Protoplasmic and gemistocytic astrocytomas can be seen. Glial fibrillary acidic protein expression occurs in the majority of low-grade supratentorial diffuse astrocytomas. BRAFV600E mutations occur in this subgroup and have been shown in a series to portend a poorer prognosis, as late transformation to a higher grade glioma has been seen (107; 92). Other activating mutations can be seen in diffuse pediatric low-grade gliomas such as FGFR1, PTPN11, and NTRK2 fusion genes (106). The most common alterations reported to date are rearrangements in the MYB family of transcription factors (107).
Other forms of pediatric low-grade gliomas are less common. Angiocentric gliomas can be seen in both children and young adults. MYB gene alterations are present in almost all cases with QKI being the primary fusion partner (05).
Astroblastomas are now defined as a unique entity and are histologically hallmarked by the presence of GFAP positive cells with pseudorosettes (129). They can be diagnosed in childhood and have been noted to have a variety of different molecular underpinnings including MN1 rearrangements, BRAF rearrangements, and even two cases with RELA rearrangements (52). Astroblastomas are a molecularly heterogeneous group and on methylation testing they can cluster with different tumors such as pleomorphic xanthoastrocytomas and ependymomas (87).
IDH mutant low-grade astrocytomas are relatively uncommon in pediatric-aged patients, but have been increasingly recognized (87). Initially they were thought to make up less than 5% of pediatric low-grade gliomas, but this may be an underestimation. Overall, these tumors act more benignly in the pediatric age than they do in adulthood. However, they may transform over time into higher grade tumors.
Pleomorphic xanthoastrocytoma is a complex tumor composed of a mixture of histologically variable tumor cells including fibrillary astrocytomas and giant multinucleated forms (114). The multinucleated cells typically contain lipid vacuoles. Despite this pleomorphic appearance, some pleomorphic xanthoastrocytomas tend to have a good prognosis. The most common molecular underpinning of the pleomorphic xanthoastrocytomas are V600E mutations (87; 88).
The dysembryoplastic neuroepithelial tumor also is most likely to present with seizures and is characterized by the presence of columns of oligodendroglial-like cells, ganglion cells, and astrocytes. The most common molecular genetic abnormalities in dysembryoplastic neuroepithelial tumors are FGFR1 mutations including FGFR1 activating point mutations and activating gene fusions (110).
Desmoplastic infantile astrocytomas (DIA) and desmoplastic infantile gangliogliomas tend to present early in life. They have a characteristic imaging appearance in which a contrast enhancing solid nodule occurs associated with a large cystic component (126; 10). Often the large cystic component actually lies medial to the tumor nodule. The separation between desmoplastic infantile astrocytomas and desmoplastic infantile gangliogliomas is often arbitrary and on methylation analysis these tumors tend to cluster together (87). Once again, a variety of different molecularly genetic findings can be seen including BRAF mutations, such as the BRAFV600E mutation, but also BRAFV600D mutations (45; 11).
Rosette-forming glial neuronal tumors are rare and usually occur deeper in brain, including the diencephalic region. FGFR1 mutations seem to characterize the vast majority of these tumors (118).
Diffuse leptomeningeal glioneuronal tumor (DLGNT) is an increasingly recognized tumor of childhood characterized by diffuse leptomeningeal enhancement of the brain and spine. Previously identified under different nomenclatures, including diffuse leptomeningeal oligodendroglial tumors, disseminated pilocytic astrocytomas, and anaplastic astrocytomas, this tumor is separable on methylation into different subtypes (23). The relatively distinct subtypes have somewhat different prognoses. One subtype is characterized by deletions of 1p/19q, but without mutations in IDH1 and IDH2. A second subset only has abnormality in chromosome 1p. KIAA1549:BRAF fusion was thought to be ubiquitous within this tumor subgroup, but now is recognized to only occur in a subset of tumors. Other fusions have also been noted (23; 118; 15).
In the future it is unclear whether these histologically identified different subgroups will continue to exist or whether molecular classification, primarily basing classification on the molecular subtype of the tumor rather than its histology appearance, will be the main driver underlying classification.
Epidemiology
Because of the previously stated problems in determining which tumors should be considered low-grade supratentorial gliomas and the tendency for some series to include, and others to exclude, thalamic and other diencephalic glial tumors in reviews of supratentorial gliomas and neuronal and mixed neuronal-glial tumors, the exact incidence of these tumors is hard to discern (32). The incidence of childhood astrocytomas may be increasing, especially in girls (54). Approximately 25% to 30% of all childhood primary central nervous neoplasms arise in the cerebral hemispheres. In infants, this frequency is higher, as nearly 40% of tumors arise in the cerebral cortex. Of the cerebral tumors occurring in children outside the period of infancy, 40% to 50% are low-grade astrocytomas, occurring at peak incidence between the ages of eight and 12 years. Low-grade cerebral astrocytomas outnumber higher-grade glial tumors by a 3:1 or greater ratio. The reported incidence of low-grade glial cerebral tumors is changing, in part due to the wider use of epilepsy surgery. Some children with intractable epilepsy, who are believed to harbor static lesions, are found at surgery to have low-grade glial tumors, especially gangliogliomas. In some series, gangliogliomas have made up as high as 10% of all cortical gliomas diagnosed in children less than 15 years of age. The desmoplastic infantile ganglioglioma and the dysembryonic neuroepithelial tumor are lesions diagnosed predominantly in infancy, and have been increasingly reported in the past decade; as have other mixed low-grade neuronal-glial tumors. Oligodendrogliomas tend to be diagnosed later in childhood and make up less than 5% of childhood cortical tumors.
Prevention
There are no known means to prevent the development of low-grade cortical tumors. There is an association between low-grade cortical tumors and prior cranial radiation.
Diagnostic workup
Both CT and MRI are sensitive in the detection of cortical low-grade gliomas and neuronal and mixed neuronal-glial tumors (28). Low-grade glial tumors are predominantly hypodense on CT. On MRI, they are hypointense on T1-weighted sequences and hyperintense on T2-weighted sequences. Enhancement following administration of contrast agents is variable. These tumors tend to be infiltrative, but at times, on imaging, seem relatively well marginated. This is especially true for gangliogliomas, as they tend to show little or no contrast enhancement and have high T2-weighted signal abnormalities on MRI, usually without associated cystic components. The pilomyxoid variant of pilocytic astrocytoma has a dominant solid component, often with a nonenhancing component, and seems to be more frequently disseminated (78). Pleomorphic xanthoastrocytomas classically have an enhancing solid nodule that is cortically based, with apparent meningeal involvement and a deeper nonenhancing cystic component. Fibrillary low-grade astrocytomas have a more variable neuroradiographic picture, and their presence is suggested by a limited amount of associated edema and a modest amount of mass effect, as compared to overall tumor size. Oligodendrogliomas are usually hypodense or of mixed density on MR. CT can often be helpful in the diagnosis of an oligodendroglioma because the majority of these tumors show some degree of calcification.
EEG, demonstrating focal areas of electroencephalographic slowing, can be useful in suggesting the presence of an underlying neoplasm, but is of much less value in exact diagnosis and tumor localization than is CT or MRI. Intraoperative electrocorticography is often used in patients with seizures to demonstrate the extent of the epileptogenic foci, but is not terribly useful in localizing the site of tumor. The use of electrocorticography may be helpful in surgical planning, especially as regards resection of tissue around the tumor (epileptogenic foci) to control seizures. PET and SPECT have been more widely used in the evaluation of adult cortical tumors. PET is usually performed with various agents that reflect brain metabolism; the presence of a high metabolic rate in a tumor, as compared to the metabolic activity of the surrounding brain, suggests that the tumor may be relatively malignant rather than a low-grade astrocytoma. Similarly, SPECT scanning with agents that also may reflect tumor metabolism, has been used to separate high-grade from low-grade neoplasms. Neither of these techniques has been widely used in pediatrics and, at this point, cannot be used to reliably separate high-grade from low-grade tumors. There is some evidence that pilocytic astrocytomas, although low-grade, will often show increased metabolism on both PET and SPECT. In addition, neither PET nor SPECT can separate low-grade gliomas from other low-grade neoplasms, radiation necrosis, or other processes in the brain (eg, infections, strokes) that can also mimic low-grade hemispheric astrocytomas.
Management
At present, the management of childhood cortical low-grade tumors and neuronal and mixed neuronal-glial tumors remains unsettled. Most observers suggest that, when possible, the treatment of choice is complete resection (34). After complete or near-complete resection, especially in pilocytic astrocytomas, most investigators recommend no further antitumor therapy. A complete total resection in cortical low-grade tumors results in survival rates greater than 90% after more than five years from diagnosis (58; 55; 53; 104; 128; 40). Survival of patients with subtotal resections is somewhat less favorable (40). Event-free survival is approximately 90% at five years, but closer to 50% at 10 years, and is considerably lower at 10 years in the 10% to 20% range in those who have had partial resections or biopsies (40). Gross total resections are possible in 40% to 80% of hemispheric tumors, but in a lesser number of patients with diencephalic or deep-seated tumors. The most effective surgical management of children with intractable seizures and low-grade gliomas remains unsettled, as it is unclear whether resection of the lesion plus the ictal focus results in better disease control or seizure control than total resection of the lesion alone (08; 100; 103).
The benefits of radiation therapy for children with low-grade cortical gliomas are unclear. The majority of studies have shown longer survival in children with subtotally resected tumors who have received radiation as compared to those treated with surgery alone (81; 117; 104), and is essentially unknown for neuronal and mixed neuronal-glial tumors. There have been attempts to develop prospective randomized studies for patients with subtotally resected tumors; in these studies, patients, after subtotal resection, were to be either randomized to observation alone or immediate postresection radiotherapy. However, the accruals on some of these studies were so poor that they had to be halted. Until such studies are completed, the benefits of immediate postoperative radiotherapy for children with partially resected low-grade tumors must be considered to be unproven. In general, those studies that have been completed have suggested that radiation therapy may prolong progression-free survival but that overall survival 10 and 20 years after treatment with resection followed by radiation is similar to the overall survival of patients treated with surgery alone. In a trial, five-year progression-free survival was 65% after radiotherapy and plateaued at 62% at 10 years (40). External fractionated radiotherapy in a study resulted in a 70% progression-free survival rate and a 97% overall survival rate at 10 years (93). Proton beam irradiation for cortical low-grade astrocytomas can, in some situations, spare irradiation to the temporal lobe, hippocampus, and hypothalamic-pituitary axis, resulting in theoretically less sequelae (44).
There is no evidence that whole-brain radiation therapy has any benefit over local radiation therapy in children with low-grade tumors. Whole-brain radiotherapy certainly carries a higher risk of neurocognitive sequelae than does local radiotherapy. Studies are being performed using more focused radiation therapy in children with residual disease after surgery (119). These studies have employed interstitial radiotherapy (71; 123) and, more recently, focused external beam radiation therapy. Although the early results with these techniques are encouraging, long-term disease control and safety, especially in children, remains unknown.
Chemotherapy has been used for children with low-grade gliomas over the past few years. Various chemotherapeutic regimens have been used, primarily in children with deep-seated (diencephalic tumors) not amenable to gross total resections. Drugs and drug combinations that may be of some utility include carboplatinum, cyclophosphamide, actinomycin and vincristine, carboplatinum and vincristine, VP 16, and a 5-drug regimen containing nitrosourea (99; 97; 79; 101; 37; 105; 80). The combination of carboplatinum and vincristine has been noted to result in a nearly 60% objective tumor shrinkage rate and a 90% to 95% initial tumor control rate in children with newly diagnosed, partially resected, low-grade tumors, including cortical low-grade gliomas (97; 94). In the majority of these studies, although chemotherapy may be of initial benefit, 50% of patients will progress within three years of the initiation of chemotherapy. For this reason and the concern that radiation therapy is more harmful in younger patients, chemotherapeutic regimens have been used predominantly in younger patients, especially in children less than five years of age. Studies are presently underway evaluating multiple different types of chemotherapy in supratentorial low-grade gliomas to determine long-term efficacy and safety. In a randomized, prospective study of 274 children without neurofibromatosis type 1 and with low-grade gliomas, the combination of thioguanine, procarbazine, lomustine, and vincristine (TPCV) was found to be at least equally as effective as carboplatin and vincristine. However, the relative toxicities of the regimens may result in choice of one treatment approach over the other. Younger age, greater tumor size, and thalamic involvement predicted poorer outcome (03). Children with neurofibromatosis type 1, treated only with carboplatin and vincristine, had a better prognosis (02). The addition of etoposide to carboplatin and vincristine did not improve overall or progression-free survival (41). Temozolomide has been studied, and results have been variable, with some studies suggesting a low rate of objective response and others suggesting a higher rate of tumor shrinkage (46; 65).The combination of carboplatin, vincristine, and temozolomide has also been used with good efficacy (16). The combination of cisplatin and etoposide has been used in four patients (90). Weekly vinblastine has also been shown to be active (73; 14; 75).
Avastin with or without irinotecan can also be effective, and in certain situations has been associated with improved clinical outcomes (96; 57; 62; 43).
Another approach actively utilized is molecular-targeted therapy blocking growth pathways believed active in tumors (51), such as the Ras-MAP Kinase pathway (MEK inhibitors and v600e inhibitors) and mTOR in both patients with and without neurofibromatosis type 1 (20; 21; 49; 48; 06; 98). The MEK inhibitors, in those with neurofibromatosis 1 and BRAF mutations, have likely shown the best efficacy (06; 31). In a phase 2 study of Selumetinib, a MEK-inhibitor, 25 children without NF1 with recurrent low-grade gliomas after treatment with carboplatin containing chemotherapy, nine (36%) achieved a radiographic partial response. The majority of the remaining either had less marked tumor shrinkage or stable disease and the two-year progression-free survival was 70±9%. All had tumors either with BRAF fusions or V600E mutations and responses were seen in both molecular tumor types. A separate arm of the study evaluating only those with visual pathway tumors is still being analyzed (31). These results have led to a prospective phase 3 randomized trial in children with newly diagnosed, non-totally resected, low-grade gliomas, including those of the visual pathway, comparing treatment with selumetinib to the combination of carboplatin and vincristine.
In the same phase 2 study of selumetinib for recurrent low-grade gliomas, a cohort of 25 children with NF1 and progressive low-grade gliomas were studied and an even better response rate and two-year progression-free survival was seen (96±4%), also leading to a newly opened, similar randomized prospective study comparing the same agents. Other MEK inhibitors are in active phase 2 study for progressive low-grade gliomas (13; 111).
For those children with recurrent V600E BRAF mutated low-grade gliomas and low-grade mixed neuronal-glial tumors, responses have also been seen after treatment with V600E BRAF inhibitors (66; 74), and a prospective randomized trial has recently completed accrual comparing the combination of dabrafenib, a BRAF-inhibitor and trametinib, a MEK-inhibitor to carboplatin and vincristine chemotherapy. The results in children with BRAF mutated low-grade gliomas and glioneuronal tumors demonstrated the superiority of the combination to chemotherapy in both response and progression-free survival. Patients who received dual molecular-targeted therapy also had better overall quality-of-life scores than those receiving chemotherapy (12). In still another study using a second generation BRAF-inhibitor, tovarafenib, a high-response rate was seen even in children already treated with and progressing after receiving MEK-inhibitors or first generation BRAF V600E inhibitors (67). The use of one V600E BRAF inhibitor, sorafenib, resulted in paradoxic tumor activation in BRAF-fusion low-grade gliomas, and such treatment is contraindicated (63). The toxicity profiles of BRAF-inhibitors and MEK inhibitors are different from most chemotherapies, and rash is a frequent side-effect. The long-term sequelae of such biological therapies are not well characterized. For children with symptomatic subependymal astrocytomas and tuberous sclerosis, agents that inhibit mTOR have been shown to cause significant reductions in tumor size, eliminating or delaying the need for surgery (72; 35).
The surgical management of children with recurrent or intractable seizure and known low-grade lesions remains somewhat debatable (42; 09). Removal of the lesion itself may result in excellent seizure control. However, there are some retrospective studies using historical controls that suggest that resection of the lesion plus the epileptogenic focus, as determined by electrocorticography, is more effective in long-term epilepsy control than is the removal of the lesion alone. Preliminary evidence also suggests that surgical removal, using electrocorticography, may also allow for safer, more extensive resections.
Outcomes
The location of the tumor, extent of surgical resection, and employment of radiation therapy have all been related to tumor outcome, but in a highly interrelated fashion. Bithalamic involvement predicts poor outcome (108; 03). Some studies have found that gross surgical resection is related to improved survival, especially in younger patients. Laws and colleagues suggested that a point scale, based on a personality change, the level of consciousness at the time of diagnosis, the extent of resection, tumor site, and postoperative status could predict long-term (15-year) survival (77). Using this type of point system, "good-risk" patients had greater than a 50% predicted 15-year survival as compared to 16% for those patients with "average" or "poor-risk" disease. This point system has not been widely employed by others. In an attempt to unravel which clinical factors independently affect outcome, multicentered studies have been completed. In 518 patients evaluated prospectively by the Children’s Oncology Group, gross total resection without residual disease was the predominant predictor of progression survival; on univariate analysis, juvenile pilocytic astrocytoma and gangllioma histology also were associated with better outcomes (128). Similar findings were found in a large European series (40). A European international study of 1044 children found that chiasmatic/postchiasmatic location was a predictor of poor disease control (26). In another international study of 639 children, young age, fibrillary astrocytoma, and subtotal resection were associated with less favorable disease control (120). Higher MIB-1 labeling index has been related to a poorer prognosis (89). However, it is conceivable that all of these clinical and histologic features will not be as important as molecular genetic findings BRAF-KIAA 1549 fusion abnormalities have been associated with a favorable prognosis, even in total resected pilocytic tumors (50), whereas BRAF v600E mutations associated with CDKN2A deletions and chromosome 7 gain have been related to poorer outcomes (92; 112; 76).
Long-term survivors may also have significant cognitive, social, and behavioral deficits (01). Surgical treatment of tumor-related temporal lobe epilepsy results in excellent seizure control in patients with totally removed tumors. Poorer seizure control occurs in patients with more than 10 years of epilepsy prior to removal, incomplete seizure control, or a remote electroencephalographic focus (103).
Special considerations
Anesthesia
No information is available, except for the precautions taken for patients with possible increased intracranial pressure.
References
- 01
- Aarsen FK, Paquier PF, Reddinglus RD et al. Functional outcome after low-grade astrocytoma treatment in childhood. Cancer 2006;106(2):396-402. PMID 16353203
- 02
- Ater JL, Xia C, Mazewski CM, et al. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low‐grade glioma: a report from the Children's Oncology Group. Cancer 2016;122(12):1928-36. PMID 27061921
- 03
- Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol 2012;30(21):2642-7. PMID 22665535
- 04
- Bailey P, Cushing H. Classification of tumors of the glioma group on a histogenic basis with a correlated study of prognosis. Philadelphia: JB Lippincott, 1926.
- 05
- Bandopadhayay P, Ramkissoon LA, Jain P, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet 2016;48(3):273-82. PMID 26829751
- 06
- Banerjee A, Jakacki RI, Onar-Thomas A, et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a pediatric brain tumor consortium (PBTC) study. Neuro Oncol 2017;19(8):1135-44. PMID 28339824
- 07
- Becker AP, Scapulatempo-Neto C, Carloni AC, et al. KIAA1549: BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in pilocytic astrocytomas. J Neuropathol Exp Neurol 2015;74(7):743-54. PMID 26083571
- 08
- Berger MS, Ghatan S, Haglund M, Dobbins J, Ojemann GA. Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. J Neurosurg 1993;79:62-9. PMID 8315470
- 09
- Berger MS, Keles GE, Geyer J. Cerebral hemispheric tumors of childhood. Neurosurg Clin N Am 1992;3(4):839-52. PMID 1392579
- 10
- Bianchi F, Tamburrini G, Massimi L, Caldarelli M. Supratentorial tumors typical of the infantile age: desmoplastic infantile ganglioglioma (DIG) and astrocytoma (DIA). A review. Childs Nerv Syst 2016;32(10):1833-8. PMID 27659826
- 11
- Blessing MM, Blackburn PR, Krishnan C, et al. Desmoplastic infantile ganglioglioma: a MAPK pathway-driven and microglia/macrophage-rich neuroepithelial tumor. J Neuropathol Exp Neurol 2019;78(11):1011-21. PMID 31562743
- 12
- Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 2023;389(12):1108-20. PMID 37733309
- 13
- Bouffet EKM, Hargrave D, Roberts S, et al. Trametinib therapy in pediatric patients with low-grade gliomas (LGG) with BRAF gene fusion; a disease-specific cohort in the first pediatric testing of trametinib. Neuro-Oncolo 2018;20(Suppl 2):i114. PMCID PMC6012791
- 14
- Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012;30(12):1358-63. PMID 22393086
- 15
- Chiang J, Dalton J, Upadhyaya SA, et al. Chromosome arm 1q gain is an adverse prognostic factor in localized and diffuse leptomeningeal glioneuronal tumors with BRAF gene fusion and 1p deletion. Acta Neuropathol 2019;137(1):179-81. PMID: 30465258 PMID 30465258
- 16
- Chintagumpala M, Eckel SP, Krailo M, et al. A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study. Neuro Oncol 2015;17(8):1132-8. PMID 25854526
- 17
- Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from the SEER Program, 1973-2001. Cancer 2006;106:1358-63. PMID 16470608
- 18
- Cohen BH, Kaplan AM, Packer RJ. Management of intracranial neoplasms in children with neurofibromatosis type 1 and 2. The Children’s Cancer Study Group. Pediatr Neurosurg 1991;16(2):66-72. PMID 2132927
- 19
- Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013;125(6):901-10. PMID 23609006
- 20
- Dasgupta B, Dugan LL, Gutmann DH. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 2003;23(26):8949-54. PMID 14523097
- 21
- Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005;65(7):2755-60. PMID 15805275
- 22
- Davis RL, Onda K, Shubuya M, et al. Proliferation markers in gliomas: a comparison of bromodeoxyuridine, KI-67 and MIB-1. J Neurooncol 1995;24:9-12. PMID 8523082
- 23
- Deng MY, Sill M, Chiang J, et al. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathol 2018;136(2):239-53. PMID 29766299
- 24
- Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PloS ONE 2011;6(3):1-9. PMID 21479234
- 25
- Dougherty MJ, Santi M, Brose MS, et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010;12(7):621-30. PMID 20156809
- 26
- Driever PH, von Hornstein S, Pietsch T, et al. Natural history and management of low-grade glioma in NF-1 children. J Neurooncol 2010;100:199-207. PMID 20352473
- 27
- Dumas-Duport C, Scheithauer BW, Chodkiewicz JP, et al. Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients within intractable partial seizures. Neurosurgery 1988;23:545-56. PMID 3143922
- 28
- Edwards-Brown MK. Supratentorial brain tumors. In: Barkovich AJ, Naidich TP, editors. Pediatric neuroradiology. Neuroimaging Clin North Am 1994;4:437-56.
- 29
- Falkenstein F, Gessi M, Kandels D, et al. Prognostic impact of distinct genetic entities in pediatric diffuse glioma WHO-grade II-Report from the German/Swiss SIOP-LGG 2004 cohort. Int J Cancer 2020;147(8):2159-75. PMID 32239677
- 30
- Fangusaro J, Jones DT, Packer RJ, et al. Pediatric low-grade glioma: State-of-the-art and ongoing challenges. Neuro Oncol 2024;26(1):25-37. PMID 37944912
- 31
- Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019;20(7):1011-22. PMID 31151904
- 32
- Farwell JR, Dohrmann GJ, Flannery JT. Central nervous system tumors in children. Cancer 1977;40:3123-32. PMID 201364
- 33
- Fazekas JT. Treatment of grades I and II brain astrocytomas. The role of radiotherapy. Int J Radiat Oncol Biol Phys 1977;2(7-8):661-6. PMID 893171
- 34
- Fisher BJ, Leighton CC, Vujovic O, Macdonald DR, Stitt L. Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys 2001;51(3):704-10. PMID 11597812
- 35
- Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013,381(9861):125-32. PMID 23158522
- 36
- Fukuoka K, Mamatjan Y, Tatevossian R, et al. Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro Oncol 2020;22(10):1474-83. PMID 32242226
- 37
- Gajjar A, Heideman RL, Kovnar EH, et al. Response of pediatric low grade gliomas to chemotherapy. Pediatr Neurosurg 1993;19(3):113-8; discussion 119-20. PMID 8499323
- 38
- Giannini C, Scheithauer BW, Burger PC, et al. Pleomorphic xanthoastrocytoma. Cancer 1999;85:2033-45. PMID 10223246
- 39
- Gjerris F. Clinical aspects and long-term prognosis of supratentorial tumors in infancy and childhood. Acta Neurol Scand 1978;57:445-70. PMID 696234
- 40
- Gnekow AK, Falkenstein F, von Hornstein S, et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol 2012;14(10):1265-84. PMID 22942186
- 41
- Gnekow AK, Walker DA, Kandels D, et al. A European randomized controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – a final report. Eur J Cancer 2017;81:206-25. PMID 28649001
- 42
- Goldring S, Rich KM, Picker S. Experience with gliomas in patients presenting with a chronic seizure disorder. Clin Neurosurg 1986;33:15-42. PMID 3098488
- 43
- Gorsi HS, Khanna PC, Tumblin M, et al. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade gloma: a single institutional experience. Pediatr Blood Cancer 2018;65(9):e27234. PMID 29750399
- 44
- Greenberger BA, Pulsifer MB, Ebb DH, et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys 2013;89(5):1060-68. PMID 25035209
- 45
- Greer A, Foreman NK, Donson A, Davies KD, Kleinschmidt-DeMasters BK. Desmoplastic infantile astrocytoma/ganglioglioma with rare BRAF V600D mutation. Pediatr Blood Cancer 2017;64(6). PMID 27860162
- 46
- Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol 2007;9(2):161-8. PMID 17347491
- 47
- Guthrie BL, Laws ER. Supratentorial low-grade gliomas. Neurosurg Clin N Am 1990;1:37-48. PMID 2135972
- 48
- Gutmann DH. Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1. Neurology 2014;83(5):463-71. PMID 24975854
- 49
- Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Ivestig Drugs 2013;22(4):443-62. PMID 23425047
- 50
- Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011;71(1):66-72. PMID 21610142
- 51
- Hegedus B, Banerjee D, Yeh TH, et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 2008;68(5):1520-8. PMID 18316617
- 52
- Hirose T, Nobusawa S, Sugiyama K, et al. Astroblastoma: a distinct tumor entity characterized by alterations of the X chromosome and MN1 rearrangement. Brain Pathol 2018;28(5):684-94. PMID 28990708
- 53
- Hirsch JF, Sainte-Rose C, Pierre-Kahn A, et al. Benign astrocytic and oligodendrocytic changes demonstrated by computed tomography. J Neurosurg 1986;62:154-9.
- 54
- Hjalmars U, Kulldorff M, Wahlqvist Y, Lannering B. Increased incidence rates but no space-time clustering of childhood astrocytoma in Sweden, 1973-1992. Cancer 1999;85:2077-90. PMID 10223251
- 55
- Hoffman HJ. Supratentorial brain tumors in children. In: Youmans RJ, editor. Neurological surgery. Vol 2. Philadelphia: WB Saunders, 1982:2710.
- 56
- Hoshino T. A commentary on the biology and growth kinetics of low-grade and high-grade gliomas. J Neurosurg 1984;61:895-900. PMID 6491735
- 57
- Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 2013;60(5):776-82. PMID 22976922
- 58
- Jelsma R, Bucy PC. The treatment of glioblastoma multiforme of the brain. J Neurosurg 1967;27:388-400. PMID 4293835
- 59
- Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013;45(8):927-32. PMID 23817572
- 60
- Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009;28(20):2119-23. PMID 19363522
- 61
- Jones DTW, Kieran MW, Bouffet E, et al. Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol 2018;20(2):160-73. PMID 29016845
- 62
- Kalra M, Heath JA, Kellie SJ, et al. Confirmation of bevacizumab activity, and maintenance of efficacy in retreatment after subsequent relapse, in pediatric low-grade glioma. J Pediatr Hematol Oncol 2015;37(6):e341-6. PMID 26056795
- 63
- Karajannis MA, Legault G, Fisher MJ, et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol 2014;16(10):1408-16. PMID 4803676
- 64
- Kernohan JW, Mabon RF, Svien H, Adson AW. A simplified classification of the gliomas. Mayo Clin Proc 1949;24(3):71-5. PMID 18111063
- 65
- Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 2007;49(6):808-11. PMID 17588234
- 66
- Kieran MW, Bouffet E, Tabori U, Broniscer A, Cohen K, Hansford J. The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas. Ann Oncol 2016;27(6 ):552-87.
- 67
- Kilburn LB, Khuong-Quang DA, Hansford JR, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: The phase 2 FIREFLY-1 trial. Nat Med 2023. [Epub ahead of print] PMID 37978284
- 68
- Kleihues P, Burger PC, Scheithauer B, et al. Histological typing of tumors of the central nervous system. Berlin: Springer-Verlag, 1993.
- 69
- Kleinschmidt-DeMasters BK, Donson AM, Vogel H, Foreman NK. Pilomyxoid astrocytoma (PMA) shows significant differences in gene expression vs. pilocytic astrocytoma (PA) and variable tendency toward maturation to PA. Brain Pathol 2015;25(4):429-40. PMID 25521223
- 70
- Komotar RJ, Burger PC, Carson BS, et al. Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery 2004;54;72-80. PMID 14683543
- 71
- Korinthenberg R, Neuburger D, Trippel M, et al. Long-term results of brachytherapy with temporary iodine-125 seeds in children with low-grade gliomas. Int J Radiation Oncology Biol Phys 2011;79(3):1131-8. PMID 20510544
- 72
- Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363(19):1801-11. PMID 21047224
- 73
- Lafay-Cousin L, Holm S, Qaddoumi I, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 2005;103(12):2636-42. PMID 15861409
- 74
- Lassaletta A, Guerreiro Stucklin A, Ramaswamy V, et al. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. Pediatr Blood Cancer 2016a;63(11):2038-41. PMID 27398937
- 75
- Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol 2016b;34(29):3537-43. PMID 27573663
- 76
- Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade Gliomas. J Clin Oncol 2017:35(25):2934-41. PMID 28727518
- 77
- Laws ER, Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemisphere. J Neurosurg 1984;61:665-73. PMID 6470776
- 78
- Lee H, Kim JH, Suh Y-L, et al. Imaging characteristics of pilomyxoid astrocytomas in comparison with pilocytic astrocytomas. Eur J Radiol 2011;79:311-16. PMID 20619565
- 79
- Lefkowitz IB, Packer RJ, Siegel KR, et al. Results of treatment of children with relapsed gliomas with CCNU and vincristine. Cancer 1988;61:896-902. PMID 3338054
- 80
- Levin VA, Lamborn K, Wara W, et al. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children. Neuro-oncology 2000;2(1):22-8. PMID 11302250
- 81
- Liebel SA, Sheline GE, Wara WM, et al. The role of radiation therapy in the treatment of astrocytoma. Cancer 1975;35:1551-7. PMID 1148989
- 82
- Lin A, Rodriguez FJ, Karajannis MA, et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 2012;71(1):66-72. PMID 22157620
- 83
- Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97-109. PMID 17618441
- 84
- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131(6):803-20. PMID 27157931
- 85
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231-51. PMID 34185076
- 86
- Low NL, Correll JW, Hammill FJ. Tumors of the cerebral hemispheres in children. Arch Neurol 1965;13:547-54. PMID 5294966
- 87
- Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32(4):520-37. PMID 28966033
- 88
- Mackay A, Burford A, Molinari V, et al. Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the herby phase ii randomized trial. Cancer Cell 2018;33(5):829-42. PMID 29763623
- 89
- Margraf LR, Gargan L, Butt Y, Raghunathan N, Bowers DC. Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas - an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol 2011;13(7):767-74. PMID 21653594
- 90
- Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002;20(20):4209-15. PMID 12377964
- 91
- McKeever PE, Strawderman MS, Yamini B, et al. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol 1998;57(10):931-6. PMID 9786243
- 92
- Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 2015;33(9):1015-22. PMID 25667294
- 93
- Muller K, Gnekow A, Falkenstein F, et al. Radiotherapy in pediatric pilocytic astrocytomas: a subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). Strahlenther Onkol 2013;189(8):647-55. PMID 23831852
- 94
- Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997;86:747-54. PMID 9126887
- 95
- Packer RJ, Iavarone A, Jones DTW, et al. Implications of new understandings of gliomas in children and adults with nf1: report of a consensus conference. Neuro Oncol 2020;22(6):773-84. PMID 32055852
- 96
- Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevicizumab and irinotecan. Pediatr Blood Cancer 2009;52(7):791-5. PMID 19165892
- 97
- Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for progressive low grade gliomas of childhood. J Clin Oncol 1993;11:850-7. PMID 8487049
- 98
- Packer RJ, Pfister S, Bouffet E, et al. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol 2017;19(6):750-61. PMID 27683733
- 99
- Packer RJ, Sutton LN, Bilanuik LT, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol 1988;23(1):79-85. PMID 3345069
- 100
- Packer RJ, Sutton LN, Patel KM, et al. Seizure control following tumor surgery for childhood cortical low-grade gliomas. J Neurosurg 1994;80:998-1003. PMID 8189281
- 101
- Petronio J, Edwards MS, Prados M, et al. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg 1991;74:701-8. PMID 1901597
- 102
- Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008;118(5):1739-49. PMID 18398503
- 103
- Phi JH, Kim S-K, Cho B-K, et al. Long-term surgical outcomes of temporal lobe epilepsy associated with low-grade brain tumors. Cancer 2009;115:5771-9. PMID 19806640
- 104
- Pollack IF, Claassen D, Al-Shboul Q, Janosky JE, Deutsch M. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg 1995;82:536-47. PMID 7897512
- 105
- Prados MD, Edwards MS, Rabbitt J, Lamborn K, Davis RL, Levin VA. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 1997;32:235-41. PMID 9049885
- 106
- Qaddoumi I, Orisme W, Wen J, et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 2016;131(6):833-45. PMID 26810070
- 107
- Ramkissoon LA, Horowitz PM, Craig JM, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A 2013;110(20):8188-93. PMID 23633565
- 108
- Reardon DA, Gajjar A, Sanford RA, et al. Bithalamic involvement predicts poor outcome among children with thalamic glial tumors. Pediatr Neurosurg 1998;29:29-35. PMID 9867348
- 109
- Reinhardt A, Stichel D, Schrimpf D, et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 2018;136(2):273-91. PMID 29564591
- 110
- Rivera B, Gayden T, Carrot-Zhang J, et al. Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathol 2016;131(6):847-63. PMID 26920151
- 111
- Robinson NPJ, Malvar J, Gruber-Filbin M, et al. A phase I dose escalation trial of the MEK1/2 inhibitor MEK162 (binimetinib) in children with low-grade gliomas and other RAS/RAF pathways-activated tumors. Neuro-Oncol 2018;20(Suppl 2):i114.
- 112
- Roth JJ, Fierst TM, Waanders AJ, Yimei L, Biegel JA, Santi M. Whole chromosome 7 gain predicts higher risk of recurrence in pediatric pilocytic astrocytomas independently from KIAA1549-BRAF fusion status. J Neuropathol Exp Neurol 2016;75(4):306-15. PMID 26945035
- 113
- Roth JJ, Santi M, Pollock AN, et al. Chromosome band 7q34 deletions resulting in KIAA1549‐BRAF and FAM131B‐BRAF fusions in pediatric low‐grade gliomas. Brain Pathol 2015;25(2):182-92. PMID 25040262
- 114
- Russell DS, Rubinstein LJ. Pathology of tumours of the nervous system. Baltimore: Williams & Wilkins, 1989.
- 115
- Ryall S, Tabori U, Hawkins C. A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment. Brain Tumor Pathol 2017;24(2):51-61. PMID 28342104
- 116
- Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011;6(3):e17948.
- 117
- Shaw EG, Daumas-Duport C, Scheithauer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989;70:853-61. PMID 2715812
- 118
- Sievers P, Appay R, Schrimpf D, et al. Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathol 2019;138(3):497-504. PMID 31250151
- 119
- Somaza SC, Kondziolka D, Lunsford LD, Flickinger JC, Bissonette DJ, Albright AL. Early outcomes after stereotactic radiosurgery for growing pilocytic astrocytomas in children. Pediatr Neurosurg 1996;24:109-15. PMID 9144708
- 120
- Stokland T, Liu J-F, Ironside JW, et al. A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol 2010;12(12):1257-68. PMID 20861086
- 121
- Sturm D, Capper D, Andreiuolo F, et al. Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. Nat Med 2023;29(4):917-26. Erratum in: Nat Med 2023. [Epub ahead of print] PMID 36928815
- 122
- Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22(4):425-37. PMID 23079654
- 123
- Suchorska B, Ruge M, Treuer H, Sturn V, Voges J. Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection. Neuro Oncol 2011;13(10):1133-42. PMID 21868412
- 124
- Takeshima H, Kawahaara Y, Hirano H, Obara S-I, Niiro M, Kuratsu JI. Postoperative regression of desmoplastic infantile gangliogliomas: Report of two cases. Neurosurgery 2003;53:979-84. PMID 14519230
- 125
- Taratuto AL, Monges J, Lylyk P, Leiguarda R. Superficial cerebral astrocytoma attached to dura. Cancer 1984;54:2505-12. PMID 6498740
- 126
- Trehan G, Bruge H, Vinchon M, et al. MR imaging in the diagnosis of desmoplastic infantile tumor: retrospective study of six cases. AJNR Am J Neuroradiol 2004;25(6):1028-33. PMID 15205142
- 127
- VandenBerg SR, May EE, Rubinstein LJ, et al. Desmoplastic supratentorial neuroepithelial tumors of infancy with divergent differentiation potential ("desmoplastic infantile gangliogliomas"). Report on 11 cases of a distinctive embryonal tumor with favorable prognosis. J Neurosurg 1987;66(1):58-71. PMID 3097276
- 128
- Wisoff JH, Sanford RA, Heier LA, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery 2011;68:1548-55. PMID 21368693
- 129
- Wood MD, Tihan T, Perry A, et al. Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities. Brain Pathol 2018;28(2):192-202. PMID 28960623
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Roger J Packer MD
Dr. Packer of Children’s National Medical Center and George Washington University has no relevant financial relationships to disclose.
See Profile
Patient Profile
- Age range of presentation
-
- 0 month to 65+ years
- Sex preponderance
-
- male=female
- Heredity
-
- none
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-9
-
- Neoplasm of uncertain behavior of brain and spinal cord: 237.5
- ICD-10
-
- Neoplasm of uncertain or unknown behaviour of brain, supratentorial: D43.0
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuro-Oncology
Overview of neuropathology updates for infiltrating gliomas
Oct. 11, 2024
-
Infectious Disorders
Zika virus: neurologic complications
Oct. 08, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
General Child Neurology
Cerebral edema in childhood
Sep. 29, 2024
-
Neuro-Oncology
CNS germinoma
Sep. 25, 2024
-
Developmental Malformations
Vein of Galen malformations
Sep. 22, 2024
-
Neuro-Oncology
Vestibular schwannoma
Sep. 19, 2024